Kaitlyn Bader, Assistant Managing Editor

A recent JAAD case report describes congenital depigmentation and progressive posttransplant repigmentation in a child with NHEJ1-related radiosensitive SCID—a pairing not previously documented.

Verrica Pharmaceuticals and Japanese partner Torii Pharmaceutical have each dosed a first patient in COVE-3, the second pivotal phase 3 trial testing Ycanth for common warts.

Neal Bhatia, MD, led an Evolving Paradigms event on advancing multidisciplinary care in cutaneous squamous cell carcinoma to compare systemic immunotherapy data and referral practices.

At RAD 2026, Peter Lio, MD, discussed shared decision-making strategies and emerging microbiome-targeted therapies for atopic dermatitis.

Derm-Biome Pharmaceuticals reported positive preclinical results for DB-006, a small molecule reducing itch, inflammation, and IgE levels in a model of atopic dermatitis.

David Rosmarin, MD, reviewed the heterogeneous nature of chronic hand eczema, areas of unmet need in atopic dermatitis treatment, and emerging systemic options in the vitiligo pipeline at RAD 2026.

At RAD 2026, David Rosmarin, MD, discussed the unmet need in chronic hand eczema, emerging pipeline agents, and his approach to evaluating clinical trial data.

Elizabeth Buzney, MD, provides her advice for practice setup, prior authorization timelines, and patient counseling for afamelanotide treatment in erythropoietic protoporphyria.

Data from the BroADen trial suggest that targeting STAT6 through protein degradation may offer a novel oral approach to controlling type 2 inflammation in atopic dermatitis.

Jared Gollob, MD, chief medical officer at Kymera Therapeutics, discusses early efficacy signals, the phase 2b study design, and the potential clinical role of KT-621, an oral STAT6 degrader, for moderate to severe atopic dermatitis.

Elizabeth Buzney, MD, explains her approach to monitoring patients with erythropoietic protoporphyria using afamelanotide, including skin surveillance, liver function testing, seasonal treatment decisions, and sun protection counseling.

William Posten, MD, provides an overview of postoperative radiation therapy as a treatment for keloids, including dosing parameters, safety considerations, and insurance reimbursement trends.

Jared Gollob, MD, chief medical officer at Kymera Therapeutics, reviews phase 1b data for KT-621, an oral STAT6 degrader being evaluated for atopic dermatitis.

Christopher Bunick, MD, PhD, shares his insights on the FDA approval of bemotrizinol and what the ingredient's properties mean for sun protection and cosmetic elegance.

Zoe Diana Draelos, MD, discusses how to clinically distinguish Malassezia folliculitis from acne vulgaris and when to consider antifungal therapy.

The FDA finalized the addition of bemotrizinol to the OTC sunscreen monograph, approving the broad-spectrum UV filter for use at concentrations up to 6% in adults and children 6 months or older.

William Posten, MD, discusses outcomes, recurrence rates, and the importance of patient adherence in a combined surgical excision and radiation therapy protocol for keloids.

Elizabeth Buzney, MD, provides an overview of the mechanism of action, administration protocol, and clinical safety profile of afamelanotide for erythropoietic protoporphyria.

Lakshi M. Aldredge, MSN, ANP-BC, DCNP, discusses late-breaking data preseneted at SDNP on novel immune-mediated therapies for atopic dermatitis, alopecia areata, and hidradenitis suppurativa.

Deborah Sarnoff, MD, president of the Skin Cancer Foundation, discusses actinic keratosis detection, treatment, and clinician resources provided by the Skin Cancer Foundation.

Zoe Diana Draelos, MD, FAAD, discussed the clinical rationale for incorporating plant adaptogen-based skin care into rosacea management, including how an OTC serum performed alongside prescription therapies.

Phase 1/2 data from RESET-Myositis, RESET-SSc, and RESET-SLE presented at EULAR 2026 show durable immunomodulator-free responses and a consistent safety profile across indications.

Jared Gollob, MD, discusses phase 1b biomarker findings for KT-621, a STAT6 degrader in atopic dermatitis, presented at SID 2026.

Miriam Pomerantz Kadosh, MSW, LCSW, director of education and patient engagement at the Melanoma Research Foundation, outlines free resources available to dermatology practices and communities.

Deborah Sarnoff, MD, president of the Skin Cancer Foundation, shares the importance of the "Hats On for AK" social media campaign designed to bring awareness to sun protection and reducing actinic keratosis risk.

William Posten, MD, discusses the evolution of keloid treatment and the clinical outcomes he has observed with excision followed by immediate radiation therapy.

Elizabeth Buzney, MD, discusses the key reasons erythropoietic protoporphyria is frequently misdiagnosed and the consequences of prolonged diagnostic delay.

Deborah Sarnoff, MD, president of the Skin Cancer Foundation, discusses recognizing actinic keratosis, clinical indicators for biopsy, and strategies for counseling patients on cumulative sun damage in response to AK Awareness Day.

Albert Chiou, MD, MBA, reviews updates presented at SID 2026 on phase 1 data showing soquelitinib activity in prior systemic therapy failures, with a well-balanced adverse event profile vs placebo.

Neal Bhatia, MD, describes a protocol spanning antihistamine pretreatment, in-room talk anesthesia, and post-procedure skin care to improve tolerability of photodynamic therapy.